| Literature DB >> 34865638 |
Yusuke Watanabe1, Itaru Nakamura2, Yuri Miura3, Hidehiro Watanabe1.
Abstract
BACKGROUND: Despite having a high mortality rate, Asian studies about the characteristics of adult listeriosis are limited. We investigated the incidence of listeriosis per admissions, associated factors, and rate of mortality in listeriosis, compared with non-listeriosis.Entities:
Keywords: Adult; Asia; Listeria monocytogenes; Listeriosis; Ratio of neutrophil to lymphocyte; Seasonality; Steroid
Mesh:
Substances:
Year: 2021 PMID: 34865638 PMCID: PMC8647357 DOI: 10.1186/s12879-021-06926-7
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of 11 cases of listeriosis in adult
| Sex | Age (years) | Days from admission to bacteremia | Month | Underlying disease | Immunosupressant or biological therapy | Symptoms | N/L | Complication | Antibiotics | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| M | 71 | 8 | July | Cirrhosis due to hepatitis C, brain tumor, diabetes | Bethamethasone | Fever, consciousness disturbance | 11,025/831 | None | None | Death |
| F | 72 | CA | October | Rheumatoid arthritis, sjogren syndrome, hepatitis C | Prednisolone, Methotrexate | Fever, headache, joint pain | < 400/ < 400 | None | ABPC/SBT → ABPC | Lived |
| M | 64 | CA | March | Febrile neutropenia, prostate cancer | Hydrocortisone | Fever, diarrhea | 6868/754 | None | CFPM → ABPC → AMPC | Lived |
| M | 87 | CA | June | Diabetes, giant cell arteritis | Prednisolone | Fever, dizziness | 9334/535 | Meningitis | CTRX + VCM → ABPC | Death |
| M | 77 | CA | June | CKD due to nephrotic syndrome, amyloidosis, total gastric resection | Prednisolone | Fever | 14,789/753 | None | CTM + CLDM → ABPC + SMX/TMP | Lived |
| M | 82 | 27 | May | Rectal ulcer, SSS on pacemaker | None | Fever, bloody stool | 7039/848 | None | LVFX → ABPC | Lived |
| M | 88 | CA | July | CKD, aortic stent graft, valve replacement, atrophic gastritis, | None | Fever, diarrhea | 3901/795 | None | CTRX → ABPC | Lived |
| M | 63 | CA | June | CKD on hemodialysis, renal cancer, synthetic graft | None | Fever, vomiting, diarrhea | 4537/715 | None | MEPM + VCM → ABPC | Lived |
| F | 36 | CA | June | Pregnancy, ulcerous colitis | Adalimumab | Fever, bloody stool | 12,039/2293 | None | ABPC/SBT → ABPC → MEPM | Lived |
| M | 79 | 61 | September | Relapsing polychondritis | Prednisolone, Methotrexate | Fever, abdominal pain, diarrhea, convulsion | 6064/1880 | Brain abscess | PIPC/TAZ → ABPC + GM | Lived |
| M | 84 | CA | October | Combined pulmonary fibrosis and emphysema | None | Fever, dyspnea | 5364/474 | None | CTRX → ABPC | Lived |
M male; F Female; CA community-associated; CKD chronic kidney disease; N neutrophil count; L lymphocyte count; ABPC/SBT ampicillin/sulbactam; ABPC ampicillin, CFPM cefepime; AMPC amoxicillin; CTRX ceftriaxone; VCM vancomycin; CTM cefotiam; CLDM clindamycin; SMX/TMP sulfamethoxazole/trimethoprim; LVFX levofloxacin; MEPM meropenem; PIPC/TAZ piperacillin/tazobactam; GM gentamicin
Fig. 1Distribution of 11 admission months of L. monocytogenes bacteremia and 26 admission months of the pathogens other than L. monocytogenes bacteremia
Factors and outcomes associated with listeriosis and non-listeriosis
| Characteristics | Cases (n = 11) | Controls (n = 26) | Odds Ratio | P value |
|---|---|---|---|---|
| Male | 7 (63.6) | 16 (61.5) | 0.914 (0.212–3.939) | 0.603 |
| Female | 4 (36.4) | 10 (38.5) | ||
| Age, ≥ 70 years | 8 (72.7) | 25 (96.1) | 0.107 (0.01–1.175) | 0.070 |
| Warm season | 10 (90.9) | 14 (53.8) | 8.571 (0.954–77.008) | 0.033 |
| Underlying disease, n (%) | ||||
| Diabetes | 2 (18.3) | 7 (26.9) | 0.603 (0.104–3.507) | 0.454 |
| CKD | 3 (27.3) | 7 (26.9) | 1.018 (0.209–4.965) | 0.639 |
| Cirrhosis | 1 (9.1) | 0 (0.0) | 0.297 | |
| Solid tumor | 3 (27.3) | 3 (11.5) | 2.875 (0.479–17.239) | 0.236 |
| Hematogical malignancy | 0 (0.0) | 1 (3.8) | 0.694 (0.559–0.862) | 0.703 |
| Organ transplant | 0 (0.0) | 0 (0.0) | ||
| Autoimmune disease | 3 (27.3) | 3 (11.5) | 2.875 (0.479–17.239) | 0.236 |
| HIV | 0 (0.0) | 0 (0.0) | ||
| Lung disease | 1 (9.1) | 5 (19.2) | 0.420 (0.043–4.087) | 0.41 |
| Stroke | 0 (0.0) | 5 (19.2) | 0.656 (0.511–0.843) | 0.151 |
| Active gastrointestinal disease | 4 (36.4) | 3 (11.5) | 4.381 (0.785–24.453) | 0.099 |
| Coronary artery disease | 4 (36.4) | 12 (46.2) | 0.667 (0.156–2.843) | 0.429 |
| Hypertension | 4 (36.4) | 15 (57.7) | 0.419 (0.098–1.794) | 0.235 |
| Arrhythmia | 4 (36.4) | 5 (19.2) | 2.4 (0.500–11.519) | 0.241 |
| Intravascular device | 3 (27.3) | 4 (15.4) | 2.063 (0.376–11.309) | 0.339 |
| Chronic heart failure | 2 (18.3) | 7 (26.9) | 0.603 (0.104–3.507) | 0.454 |
| Perinatal | 1 (9.1) | 0 (0.0) | 0.297 | |
| Medicine, n (%) | ||||
| Steroid | 6 (54.5) | 5 (19.2) | 5.040 (1.085–23.419) | 0.042 |
| MTX | 2 (18.3) | 0 (0.0) | 0.083 | |
| Adalimumab | 1 (9.1) | 0 (0.0) | 0.297 | |
| Acid inhibitor | 10 (90.9) | 20 (76.9) | 3.0 (0.317–28.434) | 0.31 |
| Oral iron | 1 (9.1) | 3 (11.5) | 0.767 (0.071–8.299) | 0.659 |
| Symptoms, n (%) | ||||
| Fever | 11 (100.0) | 21 (80.8) | 1.524 (1.186–1.958) | 0.151 |
| Diarrhea | 4 (36.4) | 2 (7.7) | 6.857 (1.031–45.604) | 0.051 |
| Bloody stool | 2 (18.3) | 2 (7.7) | 2.667 (0.325–21.872) | 0.341 |
| Central nervous system manifestation | 2 (18.3) | 0 (0.0) | 0.083 | |
| Blood test, mean (Min–Max, SD) | ||||
| Neutrophil, /μL | 7396 (399*-14,789, 4108) | 10,225 (2892–23,016, 5298) | 0.146 | |
| Lymphocyte, /μL | 1024 (399*-2293, 595) | 709 (99–1519, 394) | 0.264 | |
| Neutrophil/Lymphocyte | 9.46 (1–19, 5.662) | 18.44 (5–56, 13.032) | 0.015 | |
| Hb, g/dL | 11.2 (8.5–14.2, 1.6) | 11.6 (6.0–15.6, 2.4) | 0.921 | |
| Platelet, × 103/μL | 177.5 (32.0–429, 127.0) | 169.8 (56.0–332.0, 85.6) | 0.821 | |
| AST, U/L | 32.0 (14–51, 14.526) | 29.48 (16–49, 10.638) | 0.618 | |
| ALT, U/L | 19.09 (4–40, 11.22) | 22.10 (7–58, 13.870) | 0.584 | |
| LDH, U/L | 326.45 (220–620, 119.277) | 305.9 (159–764, 145.781) | 0.347 | |
| CK, U/L | 150.67 (19–514, 155.482) | 70.56 (21–209, 52.415) | 0.152 | |
| Na, mmol/L | 135.82 (128–145, 5.231) | 138.77 (131–150, 4.364) | 0.096 | |
| CRP, mg/dL | 8.735 (0.6–17.9, 5.64) | 12.008 (0.3–31.5, 9.5385) | 0.418 | |
| BS, mg/dL | 154.9 (75–420, 116) | 132.84 (65–193, 38.322) | 0.353 | |
| Entry of causative microorganisms | ||||
| CRBSI | 0 (0.0) | 6 (23.1) | 0.099 | |
| UTI | 0 (0.0) | 6 (23.1) | 0.099 | |
| IE | 0 (0.0) | 2 (7.7) | 0.488 | |
| Cholecystitis | 0 (0.0) | 1 (3.8) | 0.703 | |
| Iliopsoas muscle abscess | 0 (0.0) | 1 (3.8) | 0.703 | |
| Pacemaker infection | 0 (0.0) | 1 (3.8) | 0.703 | |
| Unknown | 11 (100.0) | 9 (34.6) | < 0.001 | |
| Admission to ICU | 2 (18.3) | 5 (19.2) | 0.933 (0.152–5.739) | 0.661 |
| No administration of effective for empiric therapy | 6 (54.5) | 10 (38.5) | 0.16 | |
| 30 day mortality, n (%) | 2 (18.3) | 5 (19.2) | 0.844 (0.137–5.220) | 0.619 |
SD standard deviation; CKD chronic kidney disease; HIV human immunodeficiency virus; MTX methotrexate; Hb hemoglobin; AST aspartate aminotransferase; ALT alanine aminotransferase; LDH lactase dehydrogenase; CK creatinine kinase; Na sodium; CRP C-reactive protein, BS blood sugar; CRBSI catheter related blood stream infection; UTI urinary tract infection; IE infective endocarditis; ICU intensive care unit